Press release content from Globe Newswire. The AP news staff was not involved in its creation. Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With ... Polyphor AGJune 28, 2021 GMT Co-primary endpoint of the study objective response rate (ORR) was not met The board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.